Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921481 | 1.00 | MMP8 (0.38) | MMP8HTTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3600424 | 1.00 | MMP8 (0.38) | MMP8HTTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28231160 | 0.84 | MMP8 (0.40) | MMP8HTTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19578354 | 0.80 | CA12 (0.33) | GAATSHRKMT2AALDH1A1CTSS | |
| SCHEMBL12175227 | 0.80 | CA12 (0.33) | GAATSHRKMT2AALDH1A1CTSS | |
| SCHEMBL3373434 | 0.79 | CA1 (0.42) | GAAKMT2ACTSSCTSK | |
| SCHEMBL3528810 | 0.79 | CA1 (0.42) | GAAKMT2ACTSSCTSK | |
| SCHEMBL3528813 | 0.79 | CA1 (0.42) | GAAKMT2ACTSSCTSK | |
| SCHEMBL28787095 | 0.77 | TSHR (0.45) | MMP8HTTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27693596 | 0.76 | KDM4C (0.47) | HTTCYP1A2CYP2C9CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104877001-B | Antifungal formulations | 西尼克斯公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3498696-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARASITICIDAL COMPOUNDS | Merial, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3050874-B1 | ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL INC (US) | 2019-01-09 | — | — | EP | disclosed |
| CN-102272105-B | enantiomerically enriched aryloazol-2-yl cyanoethylamino parasiticidal compounds | 梅瑞尔公司 | 2016-09-14 | — | — | CN | disclosed |
| EP-3050874-A1 | ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | Merial, Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2364301-B1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL LTD (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8859812-B2 | Compound reagents and method for synthesizing enantiomerically enriched amino acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-14 | — | — | US | disclosed |
| US-8461176-B2 | Enantiomerically enriched aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130066109-A1 | COMPOUNDS AND RELATED METHODS OF USE | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-14 | — | — | US | disclosed |
| CN-102272105-A | enantiomerically enriched aryloazol-2-yl cyanoethylamino parasiticidal compounds | — | 2011-12-07 | — | — | CN | disclosed |
| US-20100125089-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125089-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4B1, NPY4R, CYP4X1 | MMP8 4750/4885HTT 1528/4885CYP1A2 13/4885 |
| US-20130066109-A1 | COMPOUNDS AND RELATED METHODS OF USE | BCAT2, BCAT1, AADAT | MMP8 672/4885HTT 1792/4885CYP1A2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.